Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ichthyosis Clear all
Terminated No phase listed Observational

A Multi-center, Prospective Evaluation of Infants and Children With Congenital Ichthyosis

NCT02655861
View directory record Official record
Conditions
Ichthyosis
Interventions
Observation
Other
Lead sponsor
Yale University
Other
Eligibility
Up to 3 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Negative Valence Brain Targets and Predictors of Anxiety and Depression Treatment

NCT01903447
View directory record Official record
Conditions
Internalizing Psychopathologies (IPs) Depression and Anxiety
Interventions
SSRI, CBT
Drug · Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
271 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.

NCT05932732
View directory record Official record
Conditions
Cutis Laxa Facialis, Xeroderma
Interventions
HydraFacial Syndeo System, ReGen-GF, HydraFacial Elite MD System
Device · Drug
Lead sponsor
Austin Institute for Clinical Research
Network
Eligibility
30 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Houston, Texas • Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Jul 22, 2026, 2:26 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05521438
View directory record Official record
Conditions
Netherton Syndrome
Interventions
QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle, QRX003-4% Lotion BID
Drug
Lead sponsor
Quoin Pharmaceuticals
Industry
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Recruiting Phase 2Phase 3 Interventional

Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

NCT06953466
View directory record Official record
Conditions
Netherton Syndrome
Interventions
QRX003, 4% Lotion
Drug
Lead sponsor
Quoin Pharmaceuticals
Industry
Eligibility
14 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

NCT05295732
View directory record Official record
Conditions
Ichthyosis
Interventions
TMB-001, Matching Vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
6 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Phoenix, Arizona • Palo Alto, California • Centennial, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Completed No phase listed Observational

The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases

NCT00005660
View directory record Official record
Conditions
Basal Cell Carcinoma, Keratosis Palmaris et Plantaris, Psoriasis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1977 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Not applicable Interventional

Fish Skin Compared to Cadaver Skin as Temporary Cover for Full Thickness Burns

NCT03984331
View directory record Official record
Conditions
Burns
Interventions
Fish skin, Cadaver skin
Device
Lead sponsor
Kerecis Ltd.
Industry
Eligibility
22 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Jul 22, 2026, 2:26 PM EDT
Terminated No phase listed Observational Results available

Natural History of Netherton Syndrome

NCT05902663
View directory record Official record
Conditions
Netherton Syndrome
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Rancho Santa Margarita, California • Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Not applicable Interventional

Mindfulness vs. Support Groups for Irritable Bowel Syndrome

NCT00680693
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Mindfulness training, Psycho-educational support group for women with IBS
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)

NCT02402309
View directory record Official record
Conditions
Sjögren-Larsson Syndrome
Interventions
Active topical NS2 1% dermatologic cream, Vehicle placebo 0.0% NS2 dermatologic cream
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Omaha, Nebraska • Hershey, Pennsylvania • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Jul 22, 2026, 2:26 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis

NCT04697056
View directory record Official record
Conditions
Ichthyosis
Interventions
Imsidolimab, placebo
Drug · Biological
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
7
States / cities
Palo Alto, California • New Haven, Connecticut • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional

Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT00552565
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Rezular 15mg, Placebo, Rezular
Drug
Lead sponsor
AGI Therapeutics, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2009 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Early Phase 1 Interventional Results available

An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses

NCT04549792
View directory record Official record
Conditions
Ichthyosis
Interventions
Ustekinumab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
6 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

NCT06539507
View directory record Official record
Conditions
Netherton Syndrome
Interventions
BCX17725, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
5
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Defining the Skin and Blood Biomarkers of Ichthyosis

NCT03417856
View directory record Official record
Conditions
Ichthyosis, Netherton Syndrome
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
1 Year to 60 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Enrolling by invitation No phase listed Observational

Kerecis Real-World Fish Skin Graft Registry

NCT06384183
View directory record Official record
Conditions
Wounds, Pressure Ulcer, Diabetic Foot Ulcer, Venous Leg Ulcer, Surgical Wound, Soft Tissue Reinforcement
Interventions
Kerecis Fish Skin Graft
Device
Lead sponsor
Kerecis Ltd.
Industry
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Sarasota, Florida • Greensboro, North Carolina • Beavercreek, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2024 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes

NCT02218619
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Tauroursodeoxycholic Acid (TUDCA), Sugar Pill (placebo)
Drug
Lead sponsor
Robin Goland, MD
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Terminated Phase 2 Interventional Results available

A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis

NCT03738800
View directory record Official record
Conditions
Lamellar Ichthyosis
Interventions
CD5789 Cream 200 µg/g, CD5789 Cream 100 µg/g, CD5789 Cream Vehicle
Drug
Lead sponsor
Mayne Pharma International Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
San Diego, California • Aurora, Colorado • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 22, 2026, 2:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Scaling Disorders and Other Inherited Skin Diseases

NCT00001292
View directory record Official record
Conditions
Genetic Skin Disease, Keratosis Follicularis, Lamellar Ichthyosis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Jul 22, 2026, 2:26 PM EDT
Recruiting Phase 2Phase 3 Interventional

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05789056
View directory record Official record
Conditions
Netherton Syndrome
Interventions
QRX003, 4% Lotion
Drug
Lead sponsor
Quoin Pharmaceuticals
Industry
Eligibility
14 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Recruiting No phase listed Observational

Natural History of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)

NCT06669949
View directory record Official record
Conditions
Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)
Interventions
no intervention
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Epidermal Growth Factor Receptor Inhibition for Keratinopathies

NCT06545695
View directory record Official record
Conditions
Epidermolytic Ichthyosis, Palmoplantar Keratoderma, Pachyonychia Congenita
Interventions
Erlotinib
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Not applicable Interventional

Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training

NCT05573685
View directory record Official record
Conditions
Rheumatoid Arthritis, Diabetic Neuropathy, Fibromyalgia, Irritable Bowel Syndrome
Interventions
DiNaMo Study App, Placebo App
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Jul 22, 2026, 2:26 PM EDT